Skip to main content
See every side of every news story
Published loading...Updated

J&J wins China nod for oral psoriasis pill (JNJ:NYSE)

Summary by Seeking Alpha
Johnson & Johnson (JNJ) has won China approval for Icotyde, a once-daily pill developed with Protagonist Therapeutics (PTGX) for plaque psoriasis. Read more here.

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Seeking Alpha broke the news in Ra'anana, Israel on Friday, August 28, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal